Shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) have earned an average rating of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.00.
Several equities research analysts recently issued reports on RDHL shares. Zacks Investment Research upgraded shares of REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $8.50 target price on the stock in a report on Thursday, September 6th. ValuEngine cut shares of REDHILL BIOPHAR/S from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. HC Wainwright restated a “buy” rating on shares of REDHILL BIOPHAR/S in a research note on Tuesday, July 31st. Finally, LADENBURG THALM/SH SH started coverage on shares of REDHILL BIOPHAR/S in a research note on Monday, June 25th. They set a “buy” rating and a $20.00 target price on the stock.
A hedge fund recently raised its stake in REDHILL BIOPHAR/S stock. 683 Capital Management LLC lifted its position in shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) by 22.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,042,654 shares of the biotechnology company’s stock after buying an additional 378,751 shares during the quarter. REDHILL BIOPHAR/S makes up 1.2% of 683 Capital Management LLC’s holdings, making the stock its 13th largest holding. 683 Capital Management LLC owned 9.60% of REDHILL BIOPHAR/S worth $17,424,000 at the end of the most recent quarter. Institutional investors own 22.47% of the company’s stock.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last issued its earnings results on Thursday, August 30th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.05). REDHILL BIOPHAR/S had a negative return on equity of 133.07% and a negative net margin of 564.71%. The company had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $2.77 million. As a group, analysts expect that REDHILL BIOPHAR/S will post -1.69 EPS for the current fiscal year.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
Featured Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.